Frekil

Frekil is purpose-built for a narrow but critical use case: generating real-world evidence for regulatory submissions, payer dossiers, and label expansion. Its eight-stage pipeline—from literature review to report writing—is comprehensive and tuned for observational study designs. The self-improving agents and natural language interface let biostatisticians focus on scientific decisions rather than data wrangling. We'd reach for this when your team regularly runs comparative effectiveness, post-market safety, or external control arm studies with large, messy clinical datasets. Where it bites: There's no public pricing—expect an enterprise conversation. Integration lists are absent from the website; they mention Databricks, Snowflake, and major clouds, but no pre-built connectors for common EHR or claims platforms. This means you'll likely need data engineering support to set up the initial pipeline. For small academic projects or teams lacking structured clinical data, the platform is overkill. Compared to generic analytics tools (Tableau, Databricks SQL) or statistical packages (SAS, R), Frekil understands medicine—ontologies, study designs, and bias—which saves weeks of manual coding. But it's not a full replacement for a biostatistician; it automates the process-heavy work. In practice, early adopters praise reproducibility and auditability, but the tool's value compounds only with repeated use on the same datasets. If your organization deals with a fixed dataset once, manual methods might be fine. For iterative evidence generation across multiple studies, Frekil could be transformative. The biggest caveat: you'll need to engage sales to understand true total cost.